Table 1

Demographic and clinical characteristics at baseline

 Age (years)52.8±12.7
 Female238 (82)
 Systolic blood pressure (mm Hg)131.1±21.5
 Diastolic blood pressure (mm Hg)80.2±11.1
 Body mass index26.0±5.6
DMARD therapy
 Prior DMARDs2.9±1.3
 Prior biologicals*89 (31)
 Methotrexate use223 (76)
 Methotrexate dose (mg/week)19.7±7.0
 Prednisone use84 (29)
 Prednisone dose (mg/day)8.2±3.9
 DMARD other than methotrexate96 (33)
Disease status
 Duration (years)8 (3–16)
 Rheumatoid factor positive207 (72)
 Erosive disease207 (72)
 Erythrocyte sedimentation rate (mm/h)23 (12–40)
 C-reactive protein (mg/l)8 (3–21)
Lipid levels
 Total cholesterol (mmol/l)5.12±1.02
 Triglycerides (mmol/l)1.40±0.67
 HDL cholesterol (mmol/l)1.45±0.50
 LDL cholesterol (mmol/l)3.04±0.89
 Total cholesterol/HDL ratio3.86±1.30
 apoA-I (g/l)1.58±0.36
 apoB (g/l)0.85±0.22
 apoB/apoA-I ratio0.57±0.21
  • Values are mean±SD, median (IQR) or number (%).

  • * Prior biological use consisted of infliximab and adalimumab.

  • apo, apolipoprotein; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; HDL, high-density lipoprotein; LDL, low-density lipoprotein.